Related references
Note: Only part of the references are listed.From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit
Toni K. Choueiri et al.
CLINICAL CANCER RESEARCH (2022)
Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice
Benson Chellakkan Selvanesan et al.
SCIENCE TRANSLATIONAL MEDICINE (2022)
Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma A Randomized Clinical Trial
Robin L. Jones et al.
JAMA ONCOLOGY (2022)
Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
Nicholas A. Bosma et al.
EUROPEAN UROLOGY OPEN SCIENCE (2022)
Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)
Toni K. Choueiri et al.
ONCOLOGIST (2021)
Clinical Experience and Recent Advances in the Development of Listeria-Based Tumor Immunotherapies
Mariam Oladejo et al.
FRONTIERS IN IMMUNOLOGY (2021)
Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy
Fengzhen Mo et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Therapeutic Targeting of Vasculature in the Premetastatic and Metastatic Niches Reduces Lung Metastasis
Shanawaz M. Ghouse et al.
JOURNAL OF IMMUNOLOGY (2020)
Modeling clear cell renal cell carcinoma and therapeutic implications
Melissa M. Wolf et al.
ONCOGENE (2020)
Choosing The Right Animal Model for Renal Cancer Research
Pawel Sobczuk et al.
TRANSLATIONAL ONCOLOGY (2020)
Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
Yolla Haibe et al.
FRONTIERS IN ONCOLOGY (2020)
Epidemiology of Renal Cell Carcinoma
Sandeep Anand Padala et al.
WORLD JOURNAL OF ONCOLOGY (2020)
An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma
Toni K. Choueiri et al.
ONCOLOGIST (2019)
Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment
Jing Zhao et al.
FRONTIERS IN PHARMACOLOGY (2019)
Listeria monocytogenes Cancer Vaccines: Bridging Innate and Adaptive Immunity
Zachary T. Morrow et al.
CURRENT CLINICAL MICROBIOLOGY REPORTS (2019)
Expression of CD105 cancer stem cell marker in three subtypes of renal cell carcinoma
Leili Saeednejad Zanjani et al.
CANCER BIOMARKERS (2018)
Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway
Yoshiro Itatani et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies
Peter Makhov et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend
Hanne Locy et al.
FRONTIERS IN IMMUNOLOGY (2018)
De Novo Emergence of Mesenchymal Stem-Like CD105+ Cancer Cells by Cytotoxic Agents in Human Hepatocellular Carcinoma
Yoshimoto Nomura et al.
TRANSLATIONAL ONCOLOGY (2017)
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Katherine A. Murphy et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2017)
Endoglin Is Essential for the Maintenance of Self-Renewal and Chemoresistance in Renal Cancer Stem Cells
Junhui Hu et al.
STEM CELL REPORTS (2017)
Bevacizumab Alone or in Combination With TRC105 for Patients With Refractory Metastatic Renal Cell Cancer
Tanya B. Dorff et al.
CANCER (2017)
Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs
Chung-Han Lee et al.
CLINICAL GENITOURINARY CANCER (2016)
CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma
Shiruyeh Schokrpur et al.
SCIENTIFIC REPORTS (2016)
Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients
Gabriela Jimenez-Valerio et al.
CELL REPORTS (2016)
Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives
S. C. Joosten et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2015)
Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: From the patient's bed to molecular mechanisms
Magdalena Buczek et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2014)
Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma
A. Saroufim et al.
BRITISH JOURNAL OF CANCER (2014)
Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy
Laurence M. Wood et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2014)
Myeloid-derived suppressor cells have a central role in attenuated Listeria monocytogenes-based immunotherapy against metastatic breast cancer in young and old mice
D. Chandra et al.
BRITISH JOURNAL OF CANCER (2013)
Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents
M. Jarosz et al.
GENE THERAPY (2013)
Listeria monocytogenes (Lm)-LLO Immunotherapies Reduce the Immunosuppressive Activity of Myeloid-derived Suppressor Cells and Regulatory T Cells in the Tumor Microenvironment
Anu Wallecha et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Estimation of rat mammary tumor volume using caliper and ultrasonography measurements
Ana Faustino-Rocha et al.
LAB ANIMAL (2013)
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
Robert J. Motzer et al.
LANCET ONCOLOGY (2013)
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Migratory Activity of CD105+ Pancreatic Cancer Cells Is Strongly Enhanced by Pancreatic Stellate Cells
Kenji Fujiwara et al.
PANCREAS (2013)
Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy
Mikayel Mkrtichyan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2013)
Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
Astrid A. M. Van der Veldt et al.
CANCER CELL (2012)
A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer
Lee S. Rosen et al.
CLINICAL CANCER RESEARCH (2012)
Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105
Laurence M. Wood et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Transforming growth factor-beta and endoglin signaling orchestrate wound healing
Manoj Valluru et al.
FRONTIERS IN PHYSIOLOGY (2011)
High Efficacy of a Listeria-Based Vaccine against Metastatic Breast Cancer Reveals a Dual Mode of Action
Sun Hee Kim et al.
CANCER RESEARCH (2009)
TGF-beta signaling in vascular biology and dysfunction
Marie-Jose Goumans et al.
CELL RESEARCH (2009)
Transforming Growth Factor-Beta 1 (TGF-β1) Induces Angiogenesis Through Vascular Endothelial Growth Factor (VEGF)-Mediated Apoptosis
Giovanni Ferrari et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2009)
An Anti-Vascular Endothelial Growth Factor Receptor 2/Fetal Liver Kinase-1 Listeria monocytogenes Anti-Angiogenesis Cancer Vaccine for the Treatment of Primary and Metastatic Her-2/neu+ Breast Tumors in a Mouse Model
Matthew M. Seavey et al.
JOURNAL OF IMMUNOLOGY (2009)
Endoglin (CD105): A marker of tumor vasculature and potential target for therapy
Nikolaos A. Dallas et al.
CLINICAL CANCER RESEARCH (2008)
Identification of a tumor-initiating stem cell population in human renal carcinomas
Benedetta Bussolati et al.
FASEB JOURNAL (2008)
Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer
Sung-Hyung Lee et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels
E Fonsatti et al.
ONCOGENE (2003)
Share Paper
